Ruchi Gandhi
Optometrist · Griffin, GANPI 1306214655
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $14,203 of the $20,623 with a category attached, or 68.9%. It is spread thinly across 27 manufacturers, the largest accounting for just 22.8%. Among optometrist clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 415 payments — averaging $49.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$5K
- Sun Pharmaceutical Industries Inc.$2K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$2K
- Bausch & Lomb Americas Inc.$2K
- Notal Vision, Inc.$2K
- AbbVie$1K
- plus $7K from 21 others
What the payments were for
- Speaking & faculty fees$1,5828%
- Travel & lodging$4,31721%
- Food & beverage$14,20369%
- Gifts$170%
- Other$5042%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 57 | $4,699 |
| Sun Pharmaceutical Industries Inc. | 127 | $2,281 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 24 | $2,280 |
| Bausch & Lomb Americas Inc. | 27 | $2,061 |
| Notal Vision, Inc. | 4 | $1,582 |
| AbbVie(2 entities) | 49 | $1,138 |
| Biotissue Holdings Inc. | 8 | $971 |
| Glaukos Corporation | 9 | $833 |
| Novartis | 27 | $582 |
| Johnson & Johnson Vision Care, Inc. | 9 | $574 |
| Sight Sciences, Inc. | 12 | $533 |
| Oyster Point Pharma, Inc. | 9 | $492 |
| Dompe US, Inc. | 6 | $405 |
| Coopervision Inc. | 9 | $399 |
| Tarsus Pharmaceuticals, Inc. | 7 | $349 |
| Eyevance Pharmaceuticals LLC | 4 | $339 |
| Aerie Pharmaceuticals, Inc. | 3 | $245 |
| Harrow Eye, LLC | 5 | $226 |
| Kala Pharmaceuticals, Inc. | 5 | $203 |
| Rxsight Inc | 3 | $117 |
| Visioneering Technologies, Inc. | 1 | $83 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $80 |
| ABB Con-cise Optical Group LLC | 2 | $46 |
| Thea Pharma Inc. | 2 | $45 |
| Ivantis, Inc | 1 | $25 |
| Shire North American Group Inc | 1 | $17 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,623 in reported general payments places this provider in the 95th percentile of 1,285 optometrist providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 112 | $113,632 |
| XiidraLifitegrast | 101 | $113,291 |
| LumiganBimatoprost | 194 | $111,518 |
| MieboPerfluorohexyloctane/Pf | 86 | $64,710 |
| Cyclosporine | 62 | $50,372 |
| XdemvyLotilaner | 25 | $46,838 |
| CequaCyclosporine | 60 | $37,668 |
| TyrvayaVarenicline Tartrate | 29 | $34,666 |
| RhopressaNetarsudil Mesylate | 33 | $15,840 |
| CombiganBrimonidine Tartrate/Timolol | 28 | $9,545 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 22 | $6,219 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 31 | $6,138 |
| Tobradex StTobramycin/Dexamethasone | 25 | $5,860 |
| Brimonidine Tartrate | 33 | $5,715 |
| Latanoprost | 361 | $4,537 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $1,138 | $234,696334 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $2,061 | $178,000187 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $349 | $46,83825 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $2,281 | $37,66860 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $492 | $34,66629 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $245 | $15,84033 claims |
| AlconSimbrinza | $4,699 | $6,13831 claims |
| Eyevance Pharmaceuticals LLCTobradex St | $339 | $5,86025 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,285 optometrist providers in Georgia.
Other optometrist in Griffin
- Joshua JohnstonAtlanta$993K
- John WomackCanton$931K
- Naheed AhmadRoswell$296K
- Scott MoscowRoswell$278K
- Stephen SummerowPerry$222K
- Janelle DavisonSmyrna$199K
- Keyle BrownDawsonville$182K
- Nacondus GambleFort Stewart$175K
- Amber ZaunbrecherAtlanta$99K
- Jeffrey CofieWarner Robins$93K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.